GlassScriptPhysician profile
Liss E Speziale
NPI 1992239487
$5,629.52
in general payments reported to CMS, 2019-2025
29 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $831 · 2022: $1,044 · 2023: $1,388 · 2024: $1,182 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,755.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.16 | 2021-2025 | |
| Amgen INC. | $723.90 | 2021-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $616.80 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $584.81 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $486.12 | 2021-2024 | |
| Lilly USA, LLC | $290.31 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Ironwood Pharmaceuticals, INC | $253.34 | 2021-2024 | Linzess |
| Otsuka America Pharmaceutical, INC. | $211.40 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.80 | 2022-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $196.53 | 2021-2025 | Trelegy Ellipta |
| Ardelyx, INC. | $190.86 | 2022-2024 | Ibsrela |
| Exact Sciences Corporation | $151.75 | 2024-2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $148.42 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $116.06 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $109.28 | 2023-2025 | Farxiga, Airsupra, Lokelma |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $106.42 | 2023-2024 | |
| Amarin Pharma, INC. | $67.56 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $47.48 | 2023 | Lyvispah |
| Phathom Pharmaceuticals, INC. | $45.02 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $28.45 | 2022-2024 | Veozah |
| Shield Therapeutics INC | $22.14 | 2024 | |
| Eisai INC. | $17.02 | 2025 | |
| Metacel Pharmaceuticals LLC | $16.71 | 2025 | Ozobax |
| Xeris Pharmaceuticals, INC. | $16.46 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $16.11 | 2025 | Rexulti |
| Smith+Nephew, INC. | $15.91 | 2025 | Collagenase Santyl |
| Phadia US INC. | $15.67 | 2025 | Immunocap |
| Mannkind Corporation | $15.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liss Speziale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.